Bavarian Nordic A/S
CSE:BAVA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
144.15
283.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bavarian Nordic A/S
Cost of Revenue
Bavarian Nordic A/S
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cost of Revenue
-kr2.6B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
-18%
|
|
|
Genmab A/S
CSE:GMAB
|
Cost of Revenue
-kr601m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cost of Revenue
-kr21.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-120%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cost of Revenue
-€49.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cost of Revenue
-kr9.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
See Also
What is Bavarian Nordic A/S's Cost of Revenue?
Cost of Revenue
-2.6B
DKK
Based on the financial report for Jun 30, 2024, Bavarian Nordic A/S's Cost of Revenue amounts to -2.6B DKK.
What is Bavarian Nordic A/S's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-18%
Over the last year, the Cost of Revenue growth was -43%. The average annual Cost of Revenue growth rates for Bavarian Nordic A/S have been -30% over the past three years , -53% over the past five years , and -18% over the past ten years .
You don't have any saved screeners yet
